AmCad BioMed Corporation of Taipei City at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine

AmCad BioMed Corporation

Fl. 5, No. 167, Fu Hsing N. Rd., 105 Taipei City
Telephone +886 2 27136227
Fax +886 2 25140245

This company is co-exhibitor of
Somnics UG

Hall map

MEDICA 2019 hall map (Hall 11): stand B26

Fairground map

MEDICA 2019 fairground map: Hall 11

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.01  Diagnostics
  • 01.01.07  Apparatus for sleep studies

Apparatus for sleep studies

Our products

Product category: Apparatus for sleep studies


AmCAD-UO offers 10-minute detection for obstructive sleep apnea on awake patients, helping doctors to evaluate the root cause of sleep apnea and offer assessment for moderate/severe OSA patients. With laser-guided positioning, AmCAD-UO can precisely scan upper airway and analyze the gap between normal breathing and Müller Maneuver models. AmCAD-UO system standardizes ultrasound transducer scanning to reduce intra-observer variations and make the assessment consistent.

More Less

Product category: Apparatus for sleep studies


AmCAD-UT® Detection gives physicians the tools necessary to process ultrasound images for sonographic characteristics, helping them to make more confident diagnostic decisions.

Our platform uses statistical pattern recognition and quantification methods to process sonographic images. 

AmCAD-UT® Detection analyzes images for key characteristics (i.e., hyperechoic foci, echogenicity, texture, margin, anechoic areas, height/width ratio, tumor shape, and tumor size) to provide physicians with both the visual and quantitative data.

More Less

About us

Company details

AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in March of 2015 (Ticker: 4188). AmCad is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. Moreover, AmCad is committed to developing unique products that assist medical professionals in making more accurate early diagnoses. By integrating AI with innovative hardware solutions, we aim to solve long-standing unmet medical needs. We are bolstering clinicians’ expertise with AI-driven technology. Our patented algorithms provide medical professionals detailed quantification and visualization of sonographic characteristics.
AmCad has successfully obtained numerous FDA 510(k) Clearances and CE Mark certifications for four products. AmCad's product lines include AmCAD-UT® (FDA, CE Mark, TFDA and CFDA, for thyroid cancer analysis), AmCAD-UO (FDA and CE Mark for obstructive sleep apnea detection), AmCAD-US (FDA and CE Mark for backscattered signals analysis), AmCAD-UV (FDA and CE Mark for classifying pulsatile signals and noise), and AmCAD-CA (Cytopathology analysis). The state-of-the-art pipeline aims for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis and obstructive sleep apnea.

More Less